Curated news about real-world psychedelic research, policy, and developments
Mesa isn’t a small suburb tucked behind Phoenix. It’s the third largest city in Arizona, with a police department that employs more than 800 sworn officers, a fire and medical department that’s been in operation since 1898 and an aerospace and defense corrido…
This post suggests how to use the client's emerging imagery, memories, and unconscious content during a psychedelic session to move toward therapy goals.
Today’s psychedelics bear little resemblance to 1970s counterparts. These medicines undergo rigorous clinical trials and licensed manufacturing processes.
Using simultaneous PET–MRI, McCulloch, Larsen and colleagues quantify LSD’s dose–occupancy relationship at the serotonin 2A receptor and reveal hemodynamic effects of LSD that contrast with those of psilocybin.
We’re seeing what happens when consumer demand collides with commercial interests for drugs including GLP-1s, psychedelics and testosterone. It’s a huge shift.
Most veterans in a small Stanford ibogaine study kept their PTSD gains at 12 months, but the study had no control group, and heart risks remain.
New animal research suggests the injured brain may respond favorably to injection of psilocybin.
Government-backed research into next-generation psychedelics and neuroplastogens for addictive disorders underscores the continued momentum behind this promising drug class. TAMPA, Fla., Oct. 8, 2026 /PRNewswire/ -- Psilera Inc. ("Psilera"), a leading biophar…
NEW YORK and TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) — Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is …
From psychiatric research to counterculture and secret CIA mind-control experiments, LSD makes its way back to the lab.
VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) — Optimi Health Corp. (Nasdaq: OPTH) (CSE: OPTI) (FSE: 8BN) (“Optimi” or “the Company”), a commercial-stage pharmaceutical manufacturer and clinical-stage developer of regulated psychedelic drug prod…
All-share transaction: Recognify shareholders – including atai Life Sciences, Catalio Capital Management and Sudhoff Family Office – become shareholders of AmyriAD RL-007 adds a differentiated clinical-stage cognition program in Cognitive Impairment Associate…
FDA wants ibogaine trials run in inpatient units with continuous heart monitoring because the unapproved drug can trigger dangerous heart rhythms.
From ayahuasca for mental health to poo transplants for gut health, Judith Lucy has been on a mission to feel better, but have they worked? Judith is one of Australia's most loved comedians. She's also the author of four books and the presenter of several …
An LSD trip can be sublime and life-changing; it can also be terrifying.
The U.S. Food and Drug Administration today announced a request for information (RFI) describing approaches the agency is considering for the design of early-phase clinical trials of ibogaine drug products and seeking public input on those approaches.
Partnership intended to establish a Texas-based manufacturing pathway for pharmaceutical-grade ibogaine as TIRC advances its planned U.S. development program HIGHLIGHTS Texas Ibogaine Research Corporation (“TIRC”), the wholly-owned Texas subsidiary of Psyence…
Received single high dose of psilocybin-containing mushrooms
Psychedelics show promise for depression and anxiety. Federal support is growing, but drugs are advancing at different speeds. Hope needs evidence of benefit and safety.
